A detailed history of Jpmorgan Chase & CO transactions in Fulgent Genetics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 158,567 shares of FLGT stock, worth $3.42 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
158,567
Previous 158,628 0.04%
Holding current value
$3.42 Million
Previous $3.44 Million 9.62%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$19.09 - $22.57 $1,164 - $1,376
-61 Reduced 0.04%
158,567 $3.11 Million
Q1 2024

May 10, 2024

SELL
$21.55 - $29.29 $3.81 Million - $5.18 Million
-176,775 Reduced 52.71%
158,628 $3.44 Million
Q4 2023

Feb 12, 2024

BUY
$23.64 - $30.27 $1.08 Million - $1.38 Million
45,661 Added 15.76%
335,403 $9.7 Million
Q3 2023

Nov 14, 2023

SELL
$26.74 - $40.81 $372,381 - $568,320
-13,926 Reduced 4.59%
289,742 $7.75 Million
Q2 2023

Aug 11, 2023

SELL
$28.52 - $40.7 $1.11 Million - $1.58 Million
-38,938 Reduced 11.37%
303,668 $11.2 Million
Q1 2023

May 18, 2023

BUY
$29.39 - $36.27 $755,029 - $931,776
25,690 Added 8.11%
342,606 $10.7 Million
Q1 2023

May 11, 2023

SELL
$29.39 - $36.27 $611,899 - $755,141
-20,820 Reduced 6.16%
316,916 $9.89 Million
Q4 2022

Feb 13, 2023

BUY
$29.23 - $40.28 $4.23 Million - $5.83 Million
144,660 Added 74.92%
337,736 $10.1 Million
Q3 2022

Nov 14, 2022

BUY
$37.92 - $63.74 $4.2 Million - $7.06 Million
110,804 Added 134.68%
193,076 $7.36 Million
Q2 2022

Aug 11, 2022

BUY
$47.98 - $62.75 $183,043 - $239,391
3,815 Added 4.86%
82,272 $4.49 Million
Q1 2022

May 11, 2022

BUY
$49.85 - $96.11 $2.98 Million - $5.74 Million
59,711 Added 318.53%
78,457 $4.9 Million
Q4 2021

Feb 10, 2022

SELL
$77.3 - $105.0 $30.5 Million - $41.5 Million
-394,833 Reduced 95.47%
18,746 $1.89 Million
Q3 2021

Nov 12, 2021

BUY
$74.87 - $110.87 $31 Million - $45.9 Million
413,579 New
413,579 $37.2 Million

Others Institutions Holding FLGT

About Fulgent Genetics, Inc.


  • Ticker FLGT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 30,265,800
  • Market Cap $653M
  • Description
  • Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions...
More about FLGT
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.